Aditya Bardia, MD, MPH, on Clinical Implications of Using Datopotamab Deruxtecan vs Chemotherapy for Advanced Breast Cancer

Posted: Thursday, January 11, 2024

Aditya Bardia, MD, MPH, of Massachusetts General Hospital Cancer Center, discusses practical issues surrounding the use of datopotamab deruxtecan, an antibody-drug conjugate that seems to improve progression-free survival compared with chemotherapy in previously treated patients with inoperable or metastatic hormone receptor–positive, HER2-negative breast cancer.

---